Overview
Post marketing observational study on safety of BALFAXAR vs. KCENTRA for Reversal of Vitamin K Antagonist Induced Anticoagulation in Adults Undergoing Urgent Surgery or Invasive Procedure
Eligibility
Inclusion Criteria:
- Subjects at least 18 years of age.
- Subjects on VKA treatment.
- Received 4F-PCC agent, BALFAXAR or Kcentra, for urgent reversal of within 48 hours prior to urgent surgery or invasive procedure.
Exclusion Criteria:
- History of TEE within 90 days before receipt of VKA reversal therapy.
- Subjects treated with VKA reversal therapy and not undergoing urgent invasive procedure.
